Antitumor activity of interleukin 12 against interleukin 2-transduced mouse glioma cells

Cancer Letters

Volumn 135, Issue 1, 1998, Pages 47-51

  Kikuchi, Tetsuro ^a   Joki, Tatsuhiro ^a   Akasaki, Yasuharu ^a   Abe, Toshiaki ^a   Ohno, Tsuneya ^a  

^a JIKEI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Gene transfection; Glioma; Immunotherapy; Interleukin 12; Interleukin 2

Indexed keywords

INTERLEUKIN 2; RECOMBINANT INTERLEUKIN 12;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL; CARCINOGENICITY; CONTROLLED STUDY; CYTOKINE PRODUCTION; GENETIC TRANSFECTION; GLIOMA; INTRAPERITONEAL DRUG ADMINISTRATION; MOUSE; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; ANTINEOPLASTIC AGENTS; FEMALE; GLIOMA; HUMANS; INJECTIONS, INTRAPERITONEAL; INTERLEUKIN-12; INTERLEUKIN-2; LYMPHOPENIA; MICE; MICE, INBRED A; MICE, INBRED C57BL; MICE, NUDE; MICE, SCID; NEOPLASM TRANSPLANTATION; RECOMBINANT PROTEINS; T-LYMPHOCYTES; TRANSFECTION; TUMOR CELLS, CULTURED;

EID: 0032416235     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0304-3835(98)00268-7     Document Type: Article

References (17)

1. [1] A. Brandes, M. Soesan, M. Fiorentino, Medical treatment of high grade malignant gliomas in adults: an overview, Anticancer Res. 11 (1991) 1988-1992.
2. [2] T. Aoki, K. Tashiro, S. Miyatake, T. Kinashi, T. Nakano, Y. Oda, H. Kikuchi, T. Honjo, Expression of murine interleukin 7 in a murine glioma cell line results in reduced tumorigenicity in vivo, Proc. Natl. Acad. Sci. USA 89 (1992) 3850-3854.
3. [3] H. Wakimoto, J. Abe, R. Tsunoda, M. Aoyagi, K. Hirakawa, H. Hamada, Intensified antitumor immunity by a cancer vaccine that produces granulocyte-macrophage colony-stimulating factor plus interleukin 4, Cancer Res. 56 (1996) 1828-1833.
4. [4] H. Tahara, M.T. Lotze, Antitumor effects of interleukin-12 (IL-12): applications for the immunotherapy and gene therapy of cancer, Gene Ther. 2 (1995) 96-106.
5. [5] M.J. Brunda, M.K. Gately, Interleukin-12: potential role in cancer therapy, Important Adv. Oncol. (1995) 3-18.
6. [6] M.J. Brunda, L. Luistro, R.R. Warrier, R.B. Wright, B.R. Hubbard, M. Murphy, S.F. Wolf, M.K. Gately, Antitumor and antimetastatic activity of interleukin 12 against murine tumors, J. Exp. Med. 178 (1993) 1223-1230.
7. [7] M.K. Gately, R.R. Warrier, S. Honasoge, et al., Administration of recombinant IL-12 to normal mice enhances cytolytic lymphocyte activity and induces production of IFN-gamma in vivo, Int. Immunol. 6 (1994) 157-167.
8. [8] C.L. Nastala, H.D. Edington, T.G. McKinney, H. Tahara, M.A. Nalesnik, M.J. Brunda, M.K. Gately, S.F. Wolf, R.D. Schreiber, W.J. Storkus, et al., Recombinant IL-12 administration induces tumor regression in association with IFN-gamma production, J. Immunol. 153 (1994) 1697-1706.
9. [9] H. Tahara, L. Zitvogel, W.J. Storkus, P.D. Robbins, M.T. Lotze, Murine models of cancer cytokine gene therapy using interleukin-12, Ann. N. Y. Acad. Sci. 795 (1996) 275-283.
10. [10] J.M. Wigginton, K.L. Komschlies, T.C. Back, J.L. Franco, M.J. Brunda, R.H. Wiltrout, Administration of interleukin 12 with pulse interleukin 2 and the rapid and complete eradication of murine renal carcinoma, J. Natl. Cancer Inst. 88 (1996) 38-43.
11. [11] M. Vagliani, M. Rodolfo, F. Cavallo, M. Parenza, C. Melani, G. Parmiani, G. Forni, M.P. Colombo, Interleukin 12 potentiates the curative effect of a vaccine based on interleukin 2-transduced tumor cells, Cancer Res. 56 (1996) 467-470.
12. [12] I. Pappo, H. Tahara, P.D. Robbins, M.K. Gately, S.F. Wolf, A. Barnea, M.T. Lotze, Administration of systemic or local interleukin-2 enhances the anti-tumor effects of interleukin-12 gene therapy, J. Surg. Res. 58 (1995) 218-226.
13. [13] K. Sakamoto, H. Hoshino, Y. Kiuchi, G. Nakano, Y. Nagamachi, Potential usefulness of a cultured glioma cell line induced by rous sarcoma virus in B10.A mouse as an immunotherapy model, Jpn. J. Exp. Med. 59 (1989) 173-180.
14. [14] Y. Heike, M. Takahashi, Y. Kanegae, Y. Sato, I. Saito, N. Saijo, Interleukin-2 gene transduction into freshly isolated lung adenocarcinoma cells with adenoviral vectors, Hum. Gene Ther. 8 (1997) 1-14.
15. [15] S. Nagashima, Y. Kashii, T.E. Reichert, Y. Suminami, T. Suzuki, T.L. Whiteside, Human gastric carcinoma transduced with the IL-2 gene: increased sensitivity to immune effector cells in vitro and in vivo, Int. J. Cancer 72 (1997) 174-183.
16. [16] H.F. Cserr, P.M. Knopf, Cervical lymphatics, the blood-brain barrier and the immunoreactivity of the brain: a new view, Immunol. Today 13 (1992) 507-512.
17. [17] J. Tjuvajev, B. Gansbacher, R. Desai, B. Beattie, M. Kaplitt, C. Matei, J. Koutcher, E. Gilboa, R. Blasberg, RG-2 glioma growth attenuation and severe brain edema caused by local production of interleukin-2 and interferon-gamma, Cancer Res. 55 (1995) 1902-1910.